埃莱克萨卡夫托尔/特萨卡夫托尔/伊瓦卡夫托尔对骨密度和身体构成的影响:回顾性分析
Susanne Ursula Trost1, Tasma Harindhanavudhi1, Qi Wang2
1Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
在囊性纤维化患者中,elexacaftor/tezacaftor/ivacaftor (ETI) 治疗改善了体重和脂肪质量. 然而,骨密度最初下降,但在4年后稳定,这表明长期益处.
科学领域:
- 医学研究 医学研究
- 肺部病理学 肺部病理学
- 内分泌学 在内分泌学.
背景情况:
- 囊性纤维化跨膜导电调节器 (CFTR) 调节器,如elexacaftor/tezacaftor/ivacaftor (ETI) 在患有CF (pwCF) 的患者中改善了肺功能.
- 关于ETI对CF相关的骨病和身体组成的影响仍在调查中.
研究的目的:
- 评估ETI治疗对成年CF患者骨矿物质密度和身体组成的影响.
- 评估ETI发病后随着时间的推移,骨密度和身体组成的变化.
主要方法:
- 对74名患有CF的成年人接受ETI进行了回顾性现实研究.
- 双能X射线吸收计 (DXA) 测量了ETI之前的骨密度和身体成分,并在启动后的1.5年和4年.
主要成果:
- 脊椎和部的骨密度从ETI启动前后 (1.5年) 显著下降.
- 在ETI后1.5至4年间,没有观察到骨密度的显著变化.
- 在男性和女性中观察到体重和脂肪质量的显著增加,而瘦肉质量没有变化.
结论:
- 在ETI治疗的早期,骨密度下降,但在4年后似乎稳定下来,这表明潜在的长期骨益处.
- 早期体重和脂肪量增加表明代谢适应CFTR调节.
更多相关视频
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
08:07Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments
Published on: May 31, 2017
相关概念视频
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Obese Patients
Osteoclasts in Bone Remodeling
